The value of the phenothiazine derivative chlorpromazine which was introduced into clinical psychiatry about five years ago has now been well established. Various other phenothiazine derivatives have since been studied systematically in the search for new compounds of potential clinical usefulness. One of these is perphenazine.** Promising results with a group of geriatric patients have recently been reported with this drug. (1) Chemistry Perphenazine is an amino derivative of chlorphenothiazine designated as:
The value of the phenothiazine derivative chlorpromazine which was introduced into clinical psychiatry about five years ago has now been well established. Various other phenothiazine derivatives have since been studied systematically in the search for new compounds of potential clinical usefulness. One of these is perphenazine.** Promising results with a group of geriatric patients have recently been reported with this drug. (1) Chemistry Perphenazine is an amino derivative of chlorphenothiazine designated as: 1-(2-hydroxyethyl 1)-4-(3-(2-chloro-1O-phenothiazyl)-propyl) piperazine. It is a white crystalline solid, soluble in organic and inorganic acids.
Pharmacology (2, 3) Based on the lethal dose, perphenazine is somewhat less toxic than chlorpromazine. LD so of perphenazine by the intravenous route for mice is 37 mgm/kgm, for the rat 38 mgm/kgm, and for the dog 51 mgm/kgm. Corresponding LD so for chlorpromazine are 28, 28, and 30, respectively. Both chlorpromazine and perphenazine in toxic doses administered intravenously produce death from respiratory arrest with tonic-clonic convulsions.
Perphenazine possesses considerable local anaesthetic activity in the guinea pig. It also produces irritation of the tissues when injected subcutaneously or mtramuscularly. The irritation is equivalent to that produced by chlorpromazine in equal concentration.
Perphenazine is an active inhibitor of non-specific cholinesterase. In this respect, perphenazine and chlorpromazine are approximately equal in actIvIty. Perphenazine, however, in contrast to chlorpromazine, is a more potent inhibitor of specific cholinesterase. The physiological or clinical implications of this finding are unknown at the present time.
Perphenazine shows slight anticholinergic activity and only very slight antihistaminic effects.
The drug is equal to chlorpromazine in potentiating barbiturate anaesthesia in mice. When observing the behaviour of animals under the effects of perphenazine, it was noted that the oral administration of 1 mgm/kgm produced a slight change in behaviour in the mouse, rat, cat, dog, and monkey. Three mgrn/kgm consistently brought about marked depression of behaviour, that is, inhibition of spontaneous activity, and of responsiveness. These effects were less pronounced in the cat than in the other species. The tranquillizing activity of perphenazine is about six times as great as that of chlorpromazine.
Perphenazine is also about 7 times as active as chlorpromazine in inhibiting the conditioned avoidance response in the rat without depressing the unconditioned response.
In anaesthetized dogs, perphenazine resembles chlorpromazine in producing mild hypotension, transient tachycardia, and slight adrenergic blockade when given in small doses. In larger doses, both drugs produce reversal of epinephrine effect. Both chlorpromazine and perphenazine cause cardiac stimulation and "From the Department of Psychiatry, McGill University, and the Verdun Protestant Hospital, Montreal (Dr. George E. Reed. Medical Superintendent).
""The authors wish to thank Schering Corporation Limited of Montreal for generous supplies of perphenazine, the trade mark of which is "Trilafon", peripheral vasodilatation. No significant changes were observed in the electrocardiogram of dogs with either drug.
Perphenazine is highly active against apomorphine induced emesis in the dog. (4) .
In prolonged toxicity studies (6 months) in the rat, no significant gross or microscopic pathology was noted. Some suppression of growth was recorded at high doses in the drug treated animals. All animals appeared to develop some tolerance to the depressant effects of the drug. After 6 months of oral administration of 4 mgm/kgm of perphenazine to dogs, no abnormalities of blood, kidney or liver functions have been observed. These studies will be carried on for one year.
Amphetamine sulfate possesses satisfactory antidote action in shortening hypnosis and lengthening the induction time of hypnosis. The transient slight hypotensive action of perphenazine may be counteracted by nor-epinephrine, but epinephrine is contra-indicated because its normal pressor action may be reversed by the adrenergic blocking action of phenothiazine derivatives.
Psychophysiological Observations
The psychophysiological action of perphenazine was studied by means of a test battery developed by one of the authors for the examination of phrenotropic agents and described in a previous presentation. (5) In the field of perception the critical flicker fusion frequency was decreased and the susceptibility to perceive after-images increased in healthy volunteers three hours after the oral administration of 20 mg of perphenazine. Of the motor functions tested simple reaction time was significantly increased by the drug. These findings reflect changes in fundamental perceptual functions one of which is typically found with cerebral depressants (critical flicker fusion frequency decrement) and another which is more frequently associated with the effects of cerebral excitants (after-image susceptibility increment). Characteristic of cerebral depression is the slowed psychomotor functioning as reflected in increased reaction time. Another test finding more indicative of cerebral . stimulation than depression is the improved learning and psychomotor capacity reflected in better performance in the digit symbol substitution test following the administration of perphenazine.
This drug appears to have an immediate action on the intact central nervous system which resembles a mixture of inhibitory and excitatory effects with a preponderance of inhibition.
Selection of Patients
Eighty-four female patients at the Verdun Protestant Hospital were selected for the administration of perphenazine.
Twenty-six of these patients had an onset of severe acute psychiatric disturbances within one month before the start of perphenazine therapy. These will be referred to as the "acute" patients. Several of these had actually been ill for longer periods but their symptoms had been comparatively mild.
The remainder were mostly chronic schizophrenics (70%) who had been ill for periods ranging from 3 months to 37 years with an average duration of psychotic symptoms of 12 years. These will be referred to as the "chronic" patients. Many of these had shown slight to moderate improvement with previous chlorpromazine therapy and were, in fact, receiving maintenance doses of the latter drug up to the time the present project was begun. 15 chronic patients had not had any tranquillizing medication.
The patients' ages ranged from 15 to 80 years, average 44 years. The diagnostic distribution of the patients is shown in Table 1 . --
Setting
The acute patients were treated on the closed admission ward in the beginning. There they were together with about 40 other patients. The social atmosphere on this ward is structured on the assumption that controlled permissiveness is a constructive therapeutic factor. Extensive personal interaction is promoted in this area, including group therapy twice a week. The ratio of nursing personnel to patients in this ward is 1 : 6.
Within 2 to 4 weeks about half of these patients were transferred to one of three open convalescent wards in the hospital. In these somewhat overcrowded wards the social atmosphere is structured on the assumptions that the patients can take a fair amount of responsibility, can occupy themselves usefully, and can obtain certain privileges as a result of the progress they make. On these three wards five groups are attending weekly group therapy. The ratio of nursing personnel to patients in these areas is 1 : 18.
About one-third of the patients on the admission ward were discharged from the hospital on trial before transfer to other wards had to be considered.
Two patients were transferred from the admission ward to wards for chronic patients, one to a geriatric ward, one to a ward to be described next.
Twenty of the chronic patients were situated in an old building which is one of the several closed wards for continued treatment. On this ward the patients are supervised more closely. The personality of the nurse in charge of this building determines to some extent the social climate, which is here more authoritarian in nature. The ratio of nursing personnel to patients on this ward is 1 : 17.
Another 20 patients were situated in a still older building, in which the most regressed patients reside. On this ward there is again more permissiveness, it has a small open section for those who are improving, yet the majority of patients there are inactive, autistic, or otherwise deteriorated. The ratio of nursing personnel to patients on this ward is 1 : 13.
The staff and patients on all wards were well accustomed to experimental evaluations of physical and non-physical therapeutic procedures as described in a previous paper. (6) This however does not mean that such investigations were always well accepted. In our hospital, as undoubtedly in many other treatment centres there is always noted a certain hostile skepticism towards the introduction of any new treatment project.
Administration and Dosage
Perphenazine is available for intramuscular (5 mg/cc) and oral administration (tablets). Intramuscular dosage ranged from 15 to 60 mg (0.3 mg/kg to 0.85 mg/kg) a day with no single dose higher than 20 mg (0.3 mg/kg). Oral administration ranged from 8 to 192 mg (0.08 mg/kg to 2.2 mg/kg) a day, divided into 2, 3, or 4 doses.
For the chronic patients, the frequency of administration was the same as previously with chlorpromazine. The acute patients were given the drug four times a day.
The acute patients had several dosage changes, some as many as seven increases being made where the early doses appeared insufficient for symptom control, and decreases made when progress appeared to be satisfactory or side reactions occurred.
The chronic patients seldom had more than two changes in dosage during the 6 months covered by this report. The majority received either 8 mg by mouth 3 times a day or 16 mg by mouth twice a day. No patient received perphenazine intravenously.
Fifteen patients received perphenazine intramuscularly, usually for a period of 3 to 4 days, which was followed by oral administration. 2 patients have consistently refused to take the drug by mouth but have willingly accepted injections over a period of several weeks. Sixty-nine patients received oral medication only, the ward personnel taking special precautions to ensure the actual ingestion of the drug.
To determine the duration of therapy, we were guided by the same principles as govern the treatment with chlorpromazine at this hospital; the acute patients with a short history are treated until 1 to 2 weeks after all symptoms have subsided while those with a history of paranoid symptoms or frequently recurring breakdowns receive maintenance therapy over a period of several months, or an indefinite time.
Physiological Observations
Compared with chlorpromazine, perphenazine caused only slight lowering of blood pressure and no increase in pulse rate in therapeutic doses.
No changes in body temperature were caused by the drug. EEG recordings of patients who had received perphenazine for more than 24 hours revealed a tendency to increase in synchronicity through a slight lowering of the frequency and increase of voltage.
Haemoglobin levels and leukocyte counts, done once a month, were not affected in our series. Urine sugar, acetone, and bile tests were usually negative but in two patients choluria was present consistently for eight weeks without symptoms of clinical jaundice; the choluria disappeared spontaneously. Serum alkaline phosphatase, cephalin cholesterol flocculation, serum bilirubin and blood urea nitrogen determinations were performed at regular intervals. These showed no definite pattern of change with the exception of the serum bilirubin level, where a slight tendency to rise appeared.
Side Effects and Complications
When compared with chlorpromazine, the injectable form of perphenazine was much less painful; also no reports of burning or other unpleasant sensations in the gastro-intestinal tract were received where the oral route was used, except for one patient who developed such persistent emesis that treatment had to be discontinued.
By far the most prominent side effect was the extrapyramidal syndrome. Only about 10 per cent of patients showed no evidence of this syndrome, and in over 50 per cent, it was marked enough to require either reduction of the dose and/or addition of another drug to counteract the syndrome. The symptoms tended to appear first after 4-5 days and became progressively prominent. The cogwheel phenomenon was elicited in 80 per cent. A few patients became quite disabled and not being able to feed or dress themselves, were temporarily major nursing problems, apart from feeling quite miserable because of their condition. Two or three weeks later, the extrapyramidal syndrome no longer presented a great problem; however, it was rarely completely abolished as long as the patient continued to receive 16 mg (approx. 0.25 mg/kg) of perphenazine a day or more which most of them did. The drugs used to combat the extrapyramidal syndrome were trihexyphenidyl hydrochloride (artane) 2 mg two or three times a day, diethazinehydrochloride (diparcol) 250 mg two or three times a day, and benztropine methanesulphonate (cogentin) 2 mg two or three times a day. They were considered to be of approximately equal effectiveness.
Other side effects were relatively uncommon. Drowsiness was mentioned by a few and dizziness by some others; one patient became markedly ataxic. Constipation, although not usually complained of, was probably present in a considerable number. Amenorrhea was a complaint of one patient but may have been due to emotional causes. Usually there was a gain of weight during the first week. Loss of weight occurred in some patients after 10-25 days especially in those whose self-feeding was interfered with by the extrapyramidal syndrome. Most patients' weights after the third month were not markedly different from the start.
Two patients developed transient drug rashes, after 17 days and 27 days, respectively. The medication was discontinued in the first patient and her rash disappeared within two weeks; the rash of the second patient lasted only one day and her medication was not changed.
The incidence of seizures (petit mal and grand mal) was increased in one epileptic patient while receiving the drug -this was easily counteracted by increasing the anti-convulsant medication that was given simultaneously.
A number of patients whose course of perphenazine therapy was discontinued and who were immediately changed to equivalent doses of chlorpromazine showed some untoward effects, i.e. weakness, dizziness, nausea and headache preceded in a few by paroxysmal yawning. These symptoms disappeared when the chlorpromazine was discontinued for a few days.
There were two deaths in our series. Both patients had presented special therapeutic problems before they were given perphenazine, The first patient was a 46 year old chronic schizophrenic who also had hypertensive cardiovascular disease and marked obesity. Congestive heart failure had been imminent for some time and made its clinical appearance about a month after perphenazine therapy had been started. In spite of digitalization the patient died on the fortieth day. The cause of death was considered to be cardiac decompensation due to chronic hypertensive cardiovascular disease. The dose of perphenazine had been only 8 mg (0.07 mg/kg) orally twice a day. Consent for autopsy was refused. This patient had a poor prognosis from the beginning and it was felt that the cause of death was unrelated to the administration of the drug in this case.
The other patient, aged 50 years, also very obese, had a paranoid postalcoholic psychosis and was a constant severe management problem. She had been receiving paraldehyde daily for over two years. When this drug was discontinued she became extremely aggressive and assaultive. For two days she was given chlorpromazine intramuscularly without any reduction of her excitement. Then the patient was placed on perphenazine 10 mg (0.08 mg/kg) plus reserpine 5 mg (0.04 mg/kg) intramuscularly twice a day. This combined drug therapy was continued for five days during which period of time the patient became a little more manageable but remained agitated and resistive though not confused. On the fourth day some mild extrapyramidal symptoms appeared. She died suddenly in the afternoon of the fifth day. Autopsy showed only moderate cirrhosis of the liver associated with the old alcoholism and did not reveal the cause or the mode of death.
Results
Of the 26 "acute" patients, eight were manic or hypomanic at the beginning. The presenting symptoms of excitement, overactivity, overtalkativeness, and insomnia either disappeared entirely or became insignificant within a week. Medication was discontinued in seven patients after 3 to 4 weeks, and none of these patients relapsed within the next three months. In one patient the drug is being continued for several months because of her rather unstable personality.
Four manic-depressives were depressed at the time perphenazine therapy was begun. They remained depressed or became more depressed, and the drug was discontinued after 1 to 8 weeks. They all recovered subsequently with electroconvulsive therapy.
Of the 11 "acute" patients with schizophrenic reactions, 5 recovered, 2 were much improved and 1 was improved within 2 to 4 weeks. * Three patients did not improve rapidly; 2 changed very little within three weeks and were subsequently treated with coma insulin therapy; 1 of them was discharged much improved, the other one is making satisfactory progress.
One patient was unchanged with medium doses of perphenazine for a few weeks and subsequently improved with chlorpromazine in high doses.
The "acute" patient diagnosed as epilepsy with phychosis responded favourably. The visual and auditory hallucinations which had been very disturbing to her disappeared entirely and have not recurred. This woman has been discharged home on maintenance therapy with perphenazine as well as anti-convulsants. Four continued on maintenance therapy with the drug. This was not deemed necessary in two others, owing to their good premorbid personality. The remaining two patients should have continued on maintenance therapy, but did not do so for technical reasons. Our results with perphenazine in the chronic as well as the acute patient group are shown in Table 1. ;Q"recovered" means cessation of all symptoms; "rnuch improved" means sustained reduction of symptoms to the point where the patient may be discharged from hospital; "improved" means sustained reduction. of symptoms but not to the point where the patient is able to leave the hospital; "controlled" means reduction of symptoms only for the duration of treatment.
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Discussion
In setting up the design for this investigation, we gave serious consideration to the establishment of a control series. We decided against employing doubleblind or other simultaneous control devices for the following reasons: doubleblind studies with drugs producing obvious side effects (extrapyramidal symptoms, flushing, drowsiness, etc.) are almost from the start doomed to failure unless a placebo capable of producing similar side effects is given. This would render the procedure rather cumbersome, to say the least, and would give rise to strong doubts regarding the methodology of the experiment since such powerful placebos may well have therapeutic effects of their own.
Neither did it seem to be imperative to us to use a single-blind procedure in which only the patient is unaware of the nature of the drug administered because a variety of informal ye,t reliable control measures are available in a setting such as ours for this experiment so that its results may be checked against them. To be more explicit:
(1) the investigators and the nurses had known all patients through frequent personal contacts, some of them for many years;
(2) the majority of the patients under study had received a considerable variety of other treatments in the past and we could match each patient's response with his previous responses;
(3) a great number of 'other patients in this hospital, well matched to the group under study, had concurrently been treated by other therapeutic procedures or had received no specific therapy.
These other patients could well be considered a control group although they were not given the same formal attention as the patients in the experimental series.
We did not select any male patients for this investigation because another evaluative study was simultaneously underway among our male patients. The fact that we restricted our sampling to female patients only does not mean that we would necessarily have obtained the same results with male patients. But although differences in therapeutic effectiveness of drugs in relation to the sex of the patients have been reported (though not yet confirmed), we feel such differences, if present, would only be slight.
Ideally, one would have chosen patients who had not received other ph armaco-therapy for at least a year or two prior to this study. As every investigator knows, however, this is practically an impossibility nowadays where very few patients remain, even in large hospital settings, who have not been exposed to drug therapy for varying lengths of time. We had already observed during previous experiments that patients who had been receiving an effective tranquillizing drug would rapidly become disturbed if this drug was either discontinued or replaced by a less effective agent. We could therefore assume that those patients who had been receiving another tranquillizing drug (chlorpromazine or reserpine) immediately prior to the administration of perphenazine would become more disturbed in their behaviour within a few days if perphenazine proved to be less effective than the drug they had been receiving. Continued improvement, on the other hand, would not necessarily mean that the new drug was more effective than the one they had received before because it is well known that in chronic psychiatric patients, improvement with pharmacotherapy may continue gradually over an extended period of time.
In this connection, it should be stated clearly that we do not consider this experiment as conclusive in regard to the ultimate therapeutic possibilities of perphenazine, as we are convinced that any pharmacotherapeutic procedure in chronic psychiatric patients cannot be definitely evaluated before one or two years of continued therapy have elapsed. By the same token, we are inclined to consider distinct improvement in a chronic psychotic patient taking place after only two or three weeks of pharmacotherapy as being due to other factors inherent in the treatment situation but probably not related to the effect of the drug.
Our clinical observations as regards the potency of perphenazine are in agreement with the pharmacological observations in animals where the effective ratio of perphenazine to chlorpromazine was observed to .be 1:6 or 1:7. The therapeutic doses of perphenazine in the treatment of psychotic patients were in the same order, namely, usually one-sixth or one-seventh of an equally effective dose of chlorpromazine.
Therapeutic results with perphenazine in acute psychotic conditions were as satisfactory in our sample as we would have anticipated with chlorpromazine.
Of 11 acute schizophrenic patients, 5 recovered and 2 were much improved within 4 weeks, which means that 60% of these acute patients were ready to leave the hospital within a month after being admitted.
Of the 8 acute manic patients, 7 had become asymptomatic within a month. The drug is not effective in endogenous depressions and may even intensify depressive symptoms in our experience.
Of the 42 chronic schizophrenic patients, 18 (43%) were definitely improved and another 15 (36%) temporarily improved, that is controlled, with perphenazine. Only 9 (21%) failed to show a favourable response. These figures include those patients who had already started to show improvement with other pharmacotherapeutic agents prior to the administration of perphenazine so that one may assume that perphenazine is either responsible for this improvement or is at least capable of maintaining it.
Our small sample does not permit us to draw valid conclusions as to the likelihood of certain complications such as jaundice or agranulocytosis which were not observed in our series but might occur in a larger group of patients. Extrapyramidal symptoms appeared to occur more frequently and earlier in the course of therapy than with chlorpromazine. Although always completely reversible, they were at times so severe that they required symptomatic measures to counteract them. The incidence of allergic reactions in our series was lower than with chlorpromazine. The causes for the one death in our series which may have been related to the drugs administered were unfortunately obscured by the fact that we made a methodological error in combining a potent new drug in the process of investigation with another potent drug, reserpine, without possessing either information on, or experience with, the effect of such a combination. Our only justification was the fact that this patient had presented unusual difficulties both with regard to being a danger to herself and others, and because she had proved refractory to other therapeutic procedures.
In future, we would avoid combining perphenazine with reserpine, and we would also be inclined to consider marked obesity as an added risk.
In addition it would seem to be wise to be careful with the administration of another drug for a few days after perphenazine has been discontinued.
With these precautions in mind, we feel that perphenazine is a useful and safe pharmacotherapeutic agent in the treatment of acute and chronic psychiatric disorders.
Vol. 2, No.2 Summary 1. The planning and results of an investigation of perphenazine, a new phenothiazine derivative have been presented; this study was carried out with 84 psychotic patients in a mental hospital. 2. The chemistry, pharmacology and psychophysiology of this drug are briefly described, as well as the selection of patients, the setting, administration and dosage. 3. The clinical results were similar to those one would expect to obtain with chlorpromazine, using one-sixth to one-seventh of the dose of chlorpromazine. Good to excellent results were observed in acute psychotic states except depressions. Perphenazine is also a potent therapeutic agent in the management of chronic psychotic patients. 4. Untoward reactions may occur if perphenazine is combined with large doses of reserpine, or patients are immediately changed from perphenazine to chlorpromazine. Caution might be indicated with the use of the drug in obese patients. 5. The principal clinical differences between perphenazine and chlorpromazine as observed in our series were: more frequent and earlier extrapyramidal symptoms (well controlled by various anti-Parkinsonian drugs), fewer autonomic and allergic side effects, less drowsiness, and less pain on intramuscular injection.
Be: Canadian Mental Hospitals Institute
The Canadian Psychiatric Association and the American Psychiatric Association jointly will sponsor a Canadian Mental Hospital Institute to be held at the King Edward Hotel, Toronto, January 20-24, 1958, for Canadian psychiatrists engaged in clinical administration.
The meeting will follow the pattern of the Mental Hospital Institute held each October in the United States, with emphasis on free discussion in plenary and group sessions. Registration will be limited to around one hundred and a fee of fifty dollars charged which will cover banquet, most lunches, etc. The administrative staff work will be carried out by the A.P.A. Mental Hospital Service. The theme of the Institute will be around administration in mental hospitals, including D.V.A., clinics, psychiatric units in general hospitals and special services. Suggestions for discussion topics from members of the C.P.A. through provincial director are urgently solicited.
DR. E. PEARL HOPGOOD
It is with regret we report the death of Dr. Pearl Hopgood, one of Canada's outstanding psychiatrists. Dr. Hopgood retired in 1953 after many years service as Assistant Superintendent of the Nova Scotia Hospital. Dr. Hopgood was also an organizer and supervisor of St. John Ambulance brigades in Nova Scotia and for her outstanding work in this connection she was invested at Ottawa by Lord Alexander of Tunis, Governor-General of Canada, with "Commander of the Order of St. John", the oldest order of chivalry in the Commonwealth. Dr. Hopgood was born at Malpeque, Prince Edward Island, educated at Prince of Wales College and graduated in medicine from Dalhousie University.
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